Author
Tech Arcade is a Voyager AI product that delivers bite-size tech news every day. Stories are researched and drafted by our AI newsroom, then checked against at least two independent sources, with every source linked in the article.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
Hugging Face's Microduck is a $399 open-source biped that walks, falls, and self-recovers, retrainable with reinforcement learning, while the cheapest humanoid still starts at $13,500.
The FDA cleared GENGLYCOS, Ultragenyx's first gene therapy: a one-time $2.7 million infusion targeting the root cause of glycogen storage disease type Ia.
Andreessen Horowitz just closed a $1.1B 'Machine Age' fund for chips, power, cooling and robots. The VC that said software eats the world is now betting on the hardware underneath it.
AusperBio raised $120M to push AHB-137, an antisense drug that cleared hepatitis B in 68% of a small trial, toward the first functional cure for a disease 240 million people live with.
Google's custom-chip deal could hand Marvell up to $120 billion in revenue. So why did the stock drop 7% on record earnings? The payoff doesn't land until fiscal 2029.
Gatik raised a $200M Series D led by Qatar Investment Authority and Koch to scale its driverless middle-mile trucks — with $600M in freight already contracted.
Instinct's personal AI agent hit a $2.5B valuation on a $250M Series B, up 50x in four months — as security experts flag its perpetual grip on your inbox.
Emerald AI raised $150M at a $1.05B valuation to make AI data centers throttle their own power when the grid is stressed — and says the trick could free 100+ GW on the existing U.S. grid.
Amazon is shutting down Mechanical Turk on Sept 30 after 21 years, ending the 500,000-worker 'artificial artificial intelligence' platform that helped train the AI now replacing it.
Starcloud raised $250M at a $2.3B valuation — with Nvidia joining — to run AI data centers in orbit. Free sunlight, vacuum cooling, and an 88,000-satellite dream.
Moderna and Merck's personalized mRNA cancer vaccine cleared Phase 3 in 1,137 melanoma patients — and Moderna's stock more than doubled before the full numbers were even released.
Castelion, founded by ex-SpaceX engineers in 2022, raised a $1B Series C at a $13B valuation to mass-produce its Blackbeard hypersonic missile.
XPeng's robotics unit raised over $900 million at a $6.3 billion valuation in its first external round — before the IRON humanoid has shipped a single unit.
AMD is buying Toronto startup Taalas, which etches AI model weights directly into silicon. Its first test chip ran Llama 3.1 8B at 16,960 tokens/sec — about 48x a GPU.
Unitree's Shanghai debut popped 629% intraday, valuing the humanoid robot maker near $66 billion - on 2025 net profit of about $41 million.
Nvidia is paying Poolside $6 billion to license its 'Model Factory' software, investing $1 billion more at a $12 billion valuation, and hiring 109 of the staff who built it — while insisting the deal isn't an acquisition.
Nevada cleared Tesla to run up to 5,000 paid, driverless robotaxis in Clark County — three weeks after capping it at 10. The gap between the permit and the plan is the whole story.
Takeda's Orzeyful is the first-in-class orexin agonist cleared to treat narcolepsy type 1 at its root cause — and Jefferies pegs peak sales near $2 billion.
Muon Space closed a $250M Series C at a reported $1.5B valuation to industrialize satellite production — targeting 500 spacecraft a year by 2027, up from the 11 it has flown so far.
OpenAI just let employees cash out $7 billion in stock at an $852 billion valuation — two months after a confidential SEC filing, and before a single public share trades.
Castelion — a four-year-old startup founded by SpaceX alumni — just raised $1B at a $13B valuation to mass-produce Blackbeard, a Mach-5 missile the Navy is buying for about $442,000 apiece.
The FDA approved GENGLYCOS, Ultragenyx's first gene therapy and the first treatment for the root cause of glycogen storage disease type Ia. The headline result: 31% less daily cornstarch.
Stripe is paying more than $7 billion for OpenRouter, a ~50-person startup that routes 400+ AI models and skims about 5% off every request. Here's why the payments giant just bought the AI tollbooth.
